The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
Antisense oligonucleotides in therapy for neurodegenerative disorders
Open accessAbstract
Antisense oligonucleotides are synthetic single stranded strings of nucleic acids that bind to RNA and thereby alter or reduce expression of the target RNA. They can not only reduce expression of mutant proteins by breakdown of the targeted transcript, but also restore protein expression or modify proteins through interference with pre-mRNA splicing. There has been a recent revival of interest in the use of antisense oligonucleotides to treat several neurodegenerative disorders using different approaches to prevent disease onset or halt disease progression and the first clinical trials for spinal muscular atrophy and amyotrophic lateral sclerosis showing promising results. For these trials, intrathecal delivery is being used but direct infusion into the brain ventricles and several methods of passing the blood brain barrier after peripheral administration are also under investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332
Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,181
PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen-bonding rules
Egholm, M., Buchardt, O., Christensen, L., Behrens, C., Freier, S. M., Driver, D. A., Berg, R. H., Kim, S. K., Norden, B., & Nielsen, P. E. (1993) · Nature · doi:10.1038/365566a0 · Cited by 2,079
The third helix of the Antennapedia homeodomain translocates through biological membranes.
Derossi, D., Joliot, A. H., Chassaing, G., & Prochiantz, A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34080-2 · Cited by 2,034
State of play in amyotrophic lateral sclerosis genetics
Renton, A. E., Chiò, A., & Traynor, B. J. (2014) · Nature Neuroscience · doi:10.1038/nn.3584 · Cited by 1,544
Vulpe, C., Levinson, B., Whitney, S., Packman, S., & Gitschier, J. (1993) · Nature Genetics · doi:10.1038/ng0193-7 · Cited by 1,418
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Morpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.
Stephenson, M. L., & Zamecnik, P. C. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.285 · Cited by 906
Human Neuroblasts Migrate to the Olfactory Bulb via a Lateral Ventricular Extension
Curtis, M. A., Kam, M., Nannmark, U., Anderson, M. F., Axell, M. Z., Wikkelso, C., Holtås, S., van Roon-Mom, W. M. C., Björk-Eriksson, T., Nordborg, C., et al. (2007) · Science · doi:10.1126/science.1136281 · Cited by 890
Self-citationRNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention
Donnelly, C. J., Zhang, P.-W., Pham, J. T., Haeusler, A. R., Mistry, N. A., Vidensky, S., Daley, E. L., Poth, E. M., Hoover, B., Fines, D. M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.015 · Cited by 877
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Ribonuclease H: the enzymes in eukaryotes
Cerritelli, S. M., & Crouch, R. J. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.06908.x · Cited by 814
Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., & Freier, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85268-7 · Cited by 778
The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction
Engelhardt, B., & Sorokin, L. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0177-0 · Cited by 778
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
The adhesion molecule and cytokine profile of multiple sclerosis lesions
Cannella, B., & Raine, C. S. (1995) · Annals of Neurology · doi:10.1002/ana.410370404 · Cited by 763
Antisense oligonucleotides: basic concepts and mechanisms.
Dias, N., & Stein, C. A. (2002) · PubMed · Cited by 759
Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011) · Nature · doi:10.1038/nature10485 · Cited by 741
Stability of peptide nucleic acids in human serum and cellular extracts
Demidov, V. V., Potaman, V. N., Frank-Kamenetskil, M. D., Egholm, M., Buchard, O., Sönnichsen, S. H., & Nlelsen, P. E. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90171-6 · Cited by 737
Freier, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.22.4429 · Cited by 692
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Domains of tau Protein and Interactions with Microtubules
Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E.-M., & Mandelkow, E. (1994) · Biochemistry · doi:10.1021/bi00198a017 · Cited by 655
Graham, R. K., Deng, Y., Slow, E. J., Haigh, B., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Bertram, L., Murphy, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2006.04.026 · Cited by 651
N OTCH AND P RESENILIN: Regulated Intramembrane Proteolysis Links Development and Degeneration
Selkoe, D., & Kopan, R. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131334 · Cited by 636
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Variation in alternative splicing across human tissues
Yeo, G., Holste, D., Kreiman, G., & Burge, C. B. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r74 · Cited by 584
Design of antisense oligonucleotides stabilized by locked nucleic acids
Kurreck, J. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.1911 · Cited by 577
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
Agrawal, S., Temsamani, J., & Tang, J. Y. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7595 · Cited by 561
Lagier-Tourenne, C., Baughn, M., Rigo, F., Sun, S., Liu, P., Li, H.-R., Jiang, J., Watt, A. T., Chun, S., Katz, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318835110 · Cited by 561
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
Hutchinson, E. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2985 · Cited by 532
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hökfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5633 · Cited by 520
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
Targeting nuclear RNA for in vivo correction of myotonic dystrophy
Wheeler, T. M., Leger, A. J., Pandey, S. K., MacLeod, A. R., Nakamori, M., Cheng, S. H., Wentworth, B. M., Bennett, C. F., & Thornton, C. A. (2012) · Nature · doi:10.1038/nature11362 · Cited by 502
Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.554 · Cited by 497
Peptide Nucleic Acids (PNA): Synthesis, properties and potential applications
Hyrup, B., & Nielsen, P. E. (1996) · Bioorganic & Medicinal Chemistry · doi:10.1016/0968-0896(95)00171-9 · Cited by 483
The blood–spinal cord barrier: Morphology and Clinical Implications
Bartanusz, V., Jezova, D., Alajajian, B., & Digicaylioglu, M. (2011) · Annals of Neurology · doi:10.1002/ana.22421 · Cited by 481
Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 469
Singh, N. K., Singh, N. N., Androphy, E. J., & Singh, R. N. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1333-1346.2006 · Cited by 454
Kawasaki, A. M., Casper, M. D., Freier, S. M., Lesnik, E. A., Zounes, M. C., Cummins, L. L., Gonzalez, C., & Cook, P. D. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00059a007 · Cited by 438
Levin, A. A. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00140-2 · Cited by 438
Brain pathology of spinocerebellar ataxias
Seidel, K., Siswanto, S., Brunt, E. R. P., den Dunnen, W., Korf, H.-W., & Rüb, U. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1000-x · Cited by 403
Allele-specific silencing of dominant disease genes
Miller, V. M., Xia, H., Marrs, G. L., Gouvion, C. M., Lee, G., Davidson, B. L., & Paulson, H. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1231012100 · Cited by 400
Tümer, Z., & Møller, L. B. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2009.187 · Cited by 388
The pathophysiologic role of alpha 4 integrins in vivo.
Lobb, R. R., & Hemler, M. E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117519 · Cited by 378
Cooper, J. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.5.783 · Cited by 375
Sporadic human prion diseases: molecular insights and diagnosis
Puoti, G., Bizzi, A., Forloni, G., Safar, J. G., Tagliavini, F., & Gambetti, P. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70063-7 · Cited by 365
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 349
Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.
Brown, D. A., Kang, S. H., Gryaznov, S. M., DeDionisio, L., Heidenreich, O., Sullivan, S., Xu, X., & Nerenberg, M. I. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47090-1 · Cited by 336
2′-O-methyl-modified RNAs Act as TLR7 Antagonists
Robbins, M., Judge, A., Liang, L., McClintock, K., Yaworski, E., & MacLachlan, I. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300240 · Cited by 336
Goyenvalle, A., Griffith, G., Babbs, A., Andaloussi, S. E., Ezzat, K., Avril, A., Dugovic, B., Chaussenot, R., Ferry, A., Voit, T., et al. (2015) · Nature Medicine · doi:10.1038/nm.3765 · Cited by 327
Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkinson, J. L., & Stein, C. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.6.2620 · Cited by 326
Voit, T., Topaloglu, H., Straub, V., Muntoni, F., Deconinck, N., Campion, G., De Kimpe, S. J., Eagle, M., Guglieri, M., Hood, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70195-4 · Cited by 306
Carroll, J. B., Warby, S. C., Southwell, A. L., Doty, C. N., Greenlee, S., Skotte, N., Hung, G., Bennett, C. F., Freier, S. M., & Hayden, M. R. (2011) · Molecular Therapy · doi:10.1038/mt.2011.201 · Cited by 293
EDER, P. S., DeVINE, R. J., DAGLE, J. M., & WALDER, J. A. (1991) · Antisense Research and Development · doi:10.1089/ard.1991.1.141 · Cited by 293
Pharmacokinetic Properties of 2′-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
Geary, R. S., Watanabe, T. A., Truong, L., Freier, S., Lesnik, E. A., Sioufi, N. B., Sasmor, H., Manoharan, M., & Levin, A. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38831-7 · Cited by 288
Rigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212407 · Cited by 283
Koller, E., Vincent, T. M., Chappell, A., De, S., Manoharan, M., & Bennett, C. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr089 · Cited by 281
Resistance of Morpholino Phosphorodiamidate Oligomers to Enzymatic Degradation
HUDZIAK, R. M., BAROFSKY, E., BAROFSKY, D. F., WELLER, D. L., HUANG, S.-B., & WELLER, D. D. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.267 · Cited by 275
Cossum, P. A., Sasmor, H., Dellinger, D., Truong, L., Cummins, L., Owens, S. R., Markham, P. M., Shea, J. P., & Crooke, S. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39459-0 · Cited by 265
A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse
Porensky, P. N., Mitrpant, C., McGovern, V. L., Bevan, A. K., Foust, K. D., Kaspar, B. K., Wilton, S. D., & Burghes, A. H. M. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr600 · Cited by 248
Hu, J., Matsui, M., Gagnon, K. T., Schwartz, J. C., Gabillet, S., Arar, K., Wu, J., Bezprozvanny, I., & Corey, D. R. (2009) · Nature Biotechnology · doi:10.1038/nbt.1539 · Cited by 243
Integrin modulation and signaling in leukocyte adhesion and migration
Rose, D. M., Alon, R., & Ginsberg, M. H. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00536.x · Cited by 243
Cell-Penetrating Peptides: Mechanisms and Applications
El-Andaloussi, S., Holm, T., & Langel, U. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774580796 · Cited by 242
Kanazawa, T., Akiyama, F., Kakizaki, S., Takashima, Y., & Seta, Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.036 · Cited by 241
Winkler, E. A., Sengillo, J. D., Sagare, A. P., Zhao, Z., Ma, Q., Zuniga, E., Wang, Y., Zhong, Z., Sullivan, J. S., Griffin, J. H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401595111 · Cited by 238
Physiology and pharmacological role of the blood-brain barrier.
Bernacki, J., Dobrowolska, A., Nierwińska, K., & Małecki, A. (2008) · PubMed · Cited by 238
GALBRAITH, W. M., HOBSON, W. C., GICLAS, P. C., SCHECHTER, P. J., & AGRAWAL, S. (1994) · Antisense Research and Development · doi:10.1089/ard.1994.4.201 · Cited by 238
Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice
Koval, E. D., Shaner, C., Zhang, P., du Maine, X., Fischer, K., Tay, J., Chau, B. N., Wu, G. F., & Miller, T. M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt261 · Cited by 236
Wu, B., Moulton, H. M., Iversen, P. L., Jiang, J., Li, J., Li, J., Spurney, C. F., Sali, A., Guerron, A. D., Nagaraju, K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805676105 · Cited by 236
Campbell, J. M., Bacon, T. A., & Wickstrom, E. (1990) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(90)90084-p · Cited by 230
Moulton, H. M., & Moulton, J. D. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.02.012 · Cited by 229
Characterization of ATM gene mutations in 66 ataxia telangiectasia families
Sandoval, N. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.1.69 · Cited by 226
McKay, R. A., Miraglia, L. J., Cummins, L. L., Owens, S. R., Sasmor, H., & Dean, N. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.3.1715 · Cited by 220
Claxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., Cholerton, B., Plymate, S. R., Arbuckle, M., & Craft, S. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122308 · Cited by 215
Amantana, A., Moulton, H. M., Cate, M. L., Reddy, M. T., Whitehead, T., Hassinger, J. N., Youngblood, D. S., & Iversen, P. L. (2007) · Bioconjugate Chemistry · doi:10.1021/bc070060v · Cited by 213
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1
Carpentier, A., Laigle-Donadey, F., Zohar, S., Capelle, L., Behin, A., Tibi, A., Martin-Duverneuil, N., Sanson, M., Lacomblez, L., Taillibert, S., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000475 · Cited by 212
Spinal muscular atrophy: mechanisms and therapeutic strategies
Lorson, C. L., Rindt, H., & Shababi, M. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq147 · Cited by 209
Vivo-Morpholinos: A Non-Peptide Transporter Delivers Morpholinos into a Wide Array of Mouse Tissues
Morcos, P. A., Li, Y., & Jiang, S. (2008) · BioTechniques · doi:10.2144/000113005 · Cited by 203
Liebsch, G., Landgraf, R., Engelmann, M., Lörscher, P., & Holsboer, F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)80047-2 · Cited by 191
Whitesell, L., Geselowitz, D., Chavany, C., Fahmy, B., Walbridge, S., Alger, J. R., & Neckers, L. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4665 · Cited by 183
Cellular Uptake and Intracellular Trafficking of Antisense and siRNA Oligonucleotides
Juliano, R. L., Ming, X., & Nakagawa, O. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200377d · Cited by 181
Effect of different chemically modified oligodeoxynucleotides on immune stimulation
Zhao, Q., Temsamani, J., Iadarola, P. L., Jiang, Z., & Agrawal, S. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02177-9 · Cited by 176
Tomkins, O., Friedman, O., Ivens, S., Reiffurth, C., Major, S., Dreier, J. P., Heinemann, U., & Friedman, A. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.10.006 · Cited by 175
Biopharmaceutical drug targeting to the brain
Pardridge, W. M. (2010) · Journal of Drug Targeting · doi:10.3109/10611860903548354 · Cited by 173
Antisense-based therapy for the treatment of spinal muscular atrophy
Rigo, F., Hua, Y., Krainer, A. R., & Bennett, C. F. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201207087 · Cited by 172
Mende-Mueller, L. M., Toneff, T., Hwang, S.-R., Chesselet, M.-F., & Hook, V. Y. H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-06-01830.2001 · Cited by 163
Østergaard, M. E., Southwell, A. L., Kordasiewicz, H., Watt, A. T., Skotte, N. H., Doty, C. N., Vaid, K., Villanueva, E. B., Swayze, E. E., Frank Bennett, C., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt725 · Cited by 163
Lim, S. R., & Hertel, K. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107632200 · Cited by 159
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163
Hashizume, R., Ozawa, T., Gryaznov, S. M., Bollen, A. W., Lamborn, K. R., Frey, W. H., & Deen, D. F. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-052 · Cited by 155
Southwell, A. L., Skotte, N. H., Kordasiewicz, H. B., Østergaard, M. E., Watt, A. T., Carroll, J. B., Doty, C. N., Villanueva, E. B., Petoukhov, E., Vaid, K., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.153 · Cited by 152
Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms
Aartsma-Rus, A. M., van Vliet, L., Hirschi, M., Janson, A. A. M., Heemskerk, H., de Winter, C. L., de Kimpe, S. J., van Deutekom, J. C. T., Hoen, P. A. C. ’., & van Ommen, G. B. (2008) · Molecular Therapy · doi:10.1038/mt.2008.205 · Cited by 147
α- l -ribo-Configured Locked Nucleic Acid (α-L-LNA): Synthesis and Properties
Sørensen, M. D., Kværnø, L., Bryld, T., Håkansson, A. E., Verbeure, B., Gaubert, G., Herdewijn, P. A., & Wengel, J. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0168763 · Cited by 144
Williams, J. H., Schray, R. C., Patterson, C. A., Ayitey, S., Tallent, M. K., & Lutz, G. J. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0950-09.2009 · Cited by 142
Heemskerk, H., de Winter, C., van Kuik‐Romeijn, P., Heuvelmans, N., Sabatelli, P., Rimessi, P., Braghetta, P., van Ommen, G. B., de Kimpe, S. J., Ferlini, A., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.72 · Cited by 141
Iversen, P. L., ZHU, S., MEYER, A., & Zon, G. (1992) · Antisense Research and Development · doi:10.1089/ard.1992.2.211 · Cited by 139
Phospholipid membrane permeability of peptide nucleic acid
Wittung-Stafshede, P. E., Kajanus, J., Edwards, K., Nielsen, P. E., Nordén, B., & Malmström, B. G. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00409-3 · Cited by 137
Oligonucleotide therapeutic approaches for Huntington disease
Sah, D. W. Y., & D, N. A. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45130 · Cited by 137
Recent advances in amyotrophic lateral sclerosis
Al‐Chalabi, A., & Leigh, P. N. (2000) · Current Opinion in Neurology · doi:10.1097/00019052-200008000-00006 · Cited by 136
Interferon Induction Increased through Chemical Modification of a Synthetic Polyribonucleotide
Clercq, E. D., Eckstein, F., & Merigan, T. C. (1969) · Science · doi:10.1126/science.165.3898.1137 · Cited by 135
Farr, S. A., Ripley, J. L., Rukhsana Sultana, A., Zhang, Z., Niehoff, M. L., Platt, T. L., Murphy, M. P., Morley, J. E., Kumar, V. B., & Butterfield, D. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.11.014 · Cited by 131
Banks, W. A., Farr, S. A., Butt, W., Kumar, V. B., Franko, M. W., & Morley, J. E. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29640-3 · Cited by 131
Aldrian, G. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.21.4910 · Cited by 128
Zhou, H., Janghra, N., Mitrpant, C., Dickinson, R. L., Anthony, K., Flynn, L. L., Eperon, I. C., Wilton, S. D., Morgan, J. E., & Muntoni, F. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.211 · Cited by 127
Skotte, N. H., Southwell, A. L., Østergaard, M. E., Carroll, J. B., Warby, S. C., Doty, C. N., Petoukhov, E., Vaid, K., Kordasiewicz, H. B., Watt, A. T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107434 · Cited by 127
Banks, W. A., Farr, S. A., Butt, W. R., Kumar, V. B., Franko, M. W., & Morley, J. E. (2001) · PubMed · Cited by 126
Phillips, J. A., Craig, S. J., Bayley, D., Christian, R. A., Geary, R. S., & Nicklin, P. L. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00190-1 · Cited by 121
Plasma Protein Binding of an Antisense Oligonucleotide Targeting Human ICAM-1 (ISIS 2302)
Watanabe, T. A., Geary, R. S., & Levin, A. A. (2006) · Oligonucleotides · doi:10.1089/oli.2006.16.169 · Cited by 120
Lubini, P., Zürcher, W., & Egli, M. (1994) · Chemistry & Biology · doi:10.1016/1074-5521(94)90039-6 · Cited by 114
Stabilization of the Tau Exon 10 Stem Loop Alters Pre-mRNA Splicing
Donahue, C. P., Muratore, C., Wu, J. Y., Kosik, K. S., & Wolfe, M. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600143200 · Cited by 114
Du, L., Pollard, J. M., & Gatti, R. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608616104 · Cited by 114
SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy
Winer, L. K., Srinivasan, D., Chun, S. J., Lacomis, D., Jaffa, M., Fagan, A. M., Holtzman, D. M., Wancewicz, E. V., Bennett, C. F., Bowser, R. P., et al. (2012) · JAMA Neurology · doi:10.1001/jamaneurol.2013.593 · Cited by 113
Devi, G. R., Beer, T. M., Corless, C. L., Arora, V., Weller, D. L., & Iversen, P. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2091 · Cited by 111
Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide
Evers, M. M., Pepers, B. A., van Deutekom, J. C. T., Mulders, S. A. M., den Dunnen, J. T., Aartsma-Rus, A. M., van Ommen, G. B., & van Roon‐Mom, W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024308 · Cited by 108
Self-citationIsolation and culture of microvascular endothelial cells from murine spinal cord
Ge, S., & Pachter, J. S. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.05.012 · Cited by 108
Pharmacokinetics and Tissue Distribution of a Peptide Nucleic Acid After Intravenous Administration
McMahon, B. M., Mays, D. C., Lipsky, J. J., Stewart, J. A., Fauq, A. H., & Richelson, E. (2002) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729002760070803 · Cited by 106
Seth, P. P., Siwkowski, A., Allerson, C. R., Vàsquez, G., Lee, S. S., Prakash, T. P., Kinberger, G. A., Migawa, M. T., Gaus, H. J., Bhat, B., et al. (2008) · Nucleic Acids Symposium Series · doi:10.1093/nass/nrn280 · Cited by 105
A Chemical View of Oligonucleotides for Exon Skipping and Related Drug Applications
Järver, P., O’Donovan, L., & Gait, M. J. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0454 · Cited by 102
Turner, B. J., Cheah, I. K.-M., Macfarlane, K. J., Lopes, E. C., Petratos, S., Langford, S. J., & Cheema, S. S. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02053.x · Cited by 100
Elayadi, A. N., Braasch, D. A., & Corey, D. R. (2002) · Biochemistry · doi:10.1021/bi025907j · Cited by 99
Hamm, S., Latz, E., Hangel, D., Müller, T. R., Yu, P., Golenbock, D. T., Sparwasser, T. D., Wagner, H., & Bauer, S. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.09.003 · Cited by 98
Potent Antiscrapie Activities of Degenerate Phosphorothioate Oligonucleotides
Kocisko, D. A., Vaillant, A., Lee, K. S., Arnold, K. M., Bertholet, N., Race, R., Olsen, E. A., Juteau, J., & Caughey, B. W. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1034-1044.2006 · Cited by 98
Dagle, J. M., Weeks, D. L., & Walder, J. A. (1991) · Antisense Research and Development · doi:10.1089/ard.1991.1.11 · Cited by 95
Charlier, T. D., Ball, G. F., & Balthazart, J. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3533-04.2005 · Cited by 90
Evers, M. M., Tran, H.-D., Zalachoras, I., Pepers, B. A., Meijer, O. C., den Dunnen, J. T., van Ommen, G. B., Aartsma-Rus, A. M., & van Roon‐Mom, W. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.019 · Cited by 88
Self-citationSpecific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo
Tyler, B. M., McCormick, D., Hoshall, C. V., Douglas, C. L., Jansen, K. R., Lacy, B. W., Cusack, B. M., & Richelson, E. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01575-5 · Cited by 88
Geary, R. S., Wancewicz, E. V., Matson, J. E., Pearce, M. E., Siwkowski, A. M., Swayze, E. E., & Bennett, F. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.013 · Cited by 87
Gerebtzoff, G., & Seelig, A. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci0600814 · Cited by 82
Farr, S. A., Erickson, M. A., Niehoff, M. L., Banks, W. A., & Morley, J. E. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131883 · Cited by 81
Structural origins of the exonuclease resistance of a zwitterionic RNA
Teplova, M., Wallace, S. T., Tereshko, V. A., Minasov, G., Symons, A. M., Cook, P. D., Manoharan, M., & Egli, M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14240 · Cited by 81
Du, L., Kayalı, R., Bertoni, C., Fike, F. M., Hu, H., Iversen, P. L., & Gatti, R. A. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr217 · Cited by 74
Nuclease Stability of LNA Oligonucleotides and LNA-DNA Chimeras
Frieden, M., Hansen, H. F., & Koch, T. (2003) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1081/ncn-120022731 · Cited by 74
Rembach, A., Turner, B. J., Bruce, S. J., Cheah, I. K.-M., Scott, R., Lopes, E. C., Zagami, C. J., Beart, P. M., Cheung, N. S., Langford, S. J., et al. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20191 · Cited by 72
Schlingensiepen, R., Goldbrunner, M., Szyrach, M., Stauder, G., Jachimczak, P., Bogdahn, U., Schulmeyer, F. J., Hau, P., & Schlingensiepen, K. (2005) · Oligonucleotides · doi:10.1089/oli.2005.15.94 · Cited by 69
Evers, M. M., Tran, H.-D., Zalachoras, I., Meijer, O. C., den Dunnen, J. T., van Ommen, G. B., Aartsma-Rus, A. M., & van Roon‐Mom, W. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0452 · Cited by 69
Self-citationSud, R., Geller, E. T., & Schellenberg, G. D. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.30 · Cited by 69
Stanek, L. M., Yang, W., Angus, S., Sardi, P., Hayden, M. R., Hung, G., Bennett, C. F., Cheng, S. H., & Shihabuddin, L. S. (2013) · Journal of Huntington s Disease · doi:10.3233/jhd-130057 · Cited by 68
Rifai, A., Brysch, W., Fadden, K., Clark, J., & Schlingensiepen, K.-H. (1996) · Europe PMC (PubMed Central) · Cited by 67
Osman, E. Y., Yen, P., & Lorson, C. L. (2011) · Molecular Therapy · doi:10.1038/mt.2011.232 · Cited by 67
Ma, L., Wang, D., Zhang, T.-Y., Yu, H. J., Wang, Y., Huang, S., Lee, F. S., & Chen, Z.-Y. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5348-10.2011 · Cited by 66
Broeck, B. V., Broeckhoven, C. V., & Kumar‐Singh, S. (2007) · Neurodegenerative Diseases · doi:10.1159/000105156 · Cited by 66
Osman, E. Y., Miller, M. R., Robbins, K. L., Lombardi, A., Atkinson, A. K., Brehm, A. J., & Lorson, C. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu198 · Cited by 64
Intrathecal Drug Administration in Chronic Pain Syndromes
Donck, A. V., Vranken, J. H., Puylaert, M., Hayek, S. M., Mekhail, N. A., & Zundert, J. H. M. V. (2013) · Pain Practice · doi:10.1111/papr.12111 · Cited by 63
Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected Mice
Nazor, K. E., Hung, G., Wancewicz, E. V., Giles, K., Black, C., Freier, S., Bennett, F., DeArmond, S. J., Freyman, Y., Lessard, P., et al. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2011.6 · Cited by 63
Antisense Oligonucleotide Therapy for the Treatment of C9ORF72 ALS/FTD Diseases
Riboldi, G. M., Zanetta, C., Ranieri, M., Nizzardo, M., Simone, C., Magri, F., Bresolin, N., Comi, G. P., & Corti, S. P. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8724-7 · Cited by 58
Wójcik, W., Swoveland, P. T., Zhang, X., & Vanguri, P. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20148-3 · Cited by 58
Lessons Learned From Vivo-Morpholinos: How to Avoid Vivo-Morpholino Toxicity
Ferguson, D. P., Dangott, L. J., & Lightfoot, J. T. (2014) · BioTechniques · doi:10.2144/000114167 · Cited by 57
Lee, H. J., Boado, R. J., Braasch, D. A., Corey, D. R., & Pardridge, W. M. (2002) · PubMed · Cited by 56
Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain
Ogawa, S., Brown, H. E., Okano, H. J., & Pfaff, D. W. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00096-t · Cited by 55
Nizzardo, M., Simone, C., Salani, S., Ruepp, M., Rizzo, F., Ruggieri, M., Zanetta, C., Brajkovic, S., Moulton, H. M., Mühlemann, O., et al. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.02.004 · Cited by 55
Antisense Inhibition of RNase P
Gruegelsiepe, H., Brandt, O., & Hartmann, R. K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603346200 · Cited by 52
In vivo correction of a Menkes disease model using antisense oligonucleotides
Madsen, E. C., Morcos, P. A., Mendelsohn, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710865105 · Cited by 52
Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing
Peacey, E., Rodríguez, L. C. D. L. C., Liu, Y., & Wolfe, M. S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks710 · Cited by 51
Kamashev, D. E., Ng, E., Ebralidse, K. K., & Mirzabekov, A. D. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)01153-6 · Cited by 48
Use of vivo-morpholinos for control of protein expression in the adult rat brain
Reissner, K. J., Sartor, G. C., Vazey, E. M., Dunn, T. E., Aston‐Jones, G., & Kalivas, P. W. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.10.009 · Cited by 45
Butler, M., Hayes, C. S., Chappell, A. E., Murray, S., Yaksh, T. L., & Hua, X. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.11.038 · Cited by 44
Chauhan, N. B., & Siegel, G. J. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.01.008 · Cited by 40
Sun, X., Marque, L. O., Cordner, Z. A., Pruitt, J. L., Bhat, M., Li, P. P., Kannan, G., Ladenheim, E. E., Moran, T. H., Margolis, R. L., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu349 · Cited by 40
Yaida, Y., & Nowak, T. S. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00100-p · Cited by 38
RNAi Applications in Therapy Development for Neurodegenerative Disease
Maxwell, M. M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649295 · Cited by 36
Ho, S. P., Livanov, V., Zhang, W., Li, J., & Lesher, T. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00185-5 · Cited by 33
Pao, P. W., Wee, K. B., Yee, W. C., & Pramono, Z. A. D. (2013) · Molecular Therapy · doi:10.1038/mt.2013.276 · Cited by 30
Vivo-Morpholinos Induced Transient Knockdown of Physical Activity Related Proteins
Ferguson, D. P., Schmitt, E. E., & Lightfoot, J. T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061472 · Cited by 28
Myers, K. J., Witchell, D. R., Graham, M. J., Koo, S., Butler, M., & Condon, T. P. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.10.029 · Cited by 24
Rinder, M. R., Berge, O., & Hökfelt, T. (2001) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00248-5 · Cited by 23
In Situ Entry of Oligonucleotides into Brain Cells Can Occur through a Nucleic Acid Channel
Shi, F., Gounko, N. V., Wang, X., Ronken, E., & Hoekstra, D. (2007) · Oligonucleotides · doi:10.1089/oli.2007.0034 · Cited by 20
Lashley, T., Hardy, J., & Isaacs, A. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.009 · Cited by 20
Gotkine, M., Leah, R., Einstein, O., Oded, A., Argov, Z., & Rosenmann, H. (2013) · BioMed Research International · doi:10.1155/2013/845345 · Cited by 20
Down-Regulation of Amyloid Precursor Protein by Peptide Nucleic Acid In Vivo
Boules, M., Williams, K., Gollatz, E., Fauq, A. H., & Richelson, E. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:1:123 · Cited by 14
Zalachoras, I., Grootaers, G., van Weert, L. T. C. M., Aubert, Y., de Kreij, S. R., Datson, N. A., van Roon‐Mom, W., Aartsma-Rus, A. M., & Meijer, O. C. (2013) · BMC Neuroscience · doi:10.1186/1471-2202-14-5 · Cited by 14
Advances in therapeutic RNA-targeting
van Ommen, G. B., & Aartsma-Rus, A. M. (2013) · New Biotechnology · doi:10.1016/j.nbt.2013.01.005 · Cited by 12
Antisense knockdown of calcium-dependent K+ channels in developing cerebellar Purkinje neurons
Muller, Y. L., Reitstetter, R. E., & Yool, A. J. (2000) · Developmental Brain Research · doi:10.1016/s0165-3806(00)00004-3 · Cited by 8
Cited by
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
The hnRNP family: insights into their role in health and disease
Geuens, T., Bouhy, D., & Timmerman, V. (2016) · Human Genetics · doi:10.1007/s00439-016-1683-5 · Cited by 1,093
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
Mejzini, R., Flynn, L. L., Pitout, I. L., Fletcher, S., Wilton, S. D., & Akkari, P. A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01310 · Cited by 755
Metadata
- Authors
- Evers, M. M., Toonen, L. J. A., & van Roon-Mom, W. M. C.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 87
- Pages
- 90-103
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2066796446
- Cited by
- 286
- References
- 182
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.